Jupiter is actively exploring additional strategic partnerships to expand JOTROL’s application across other neuroinflammatory and metabolic disorders, including Alzheimer’s disease and longevity ...

Ethris announces promising phase 1 results for ETH47, its mRNA therapy for uncontrolled asthma. The inhaled treatment showed strong safety and efficacy, with plans for a phase 2 trial in 2025.

Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...

Island Pharmaceuticals Ltd ( ($AU:ILA) ) has issued an announcement. Island Pharmaceuticals Ltd has progressed significantly in its ISLA-101 Phase ...

Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and ...

The data set from the double-blind phase of the RewinD-LB trial presented today at ILBDC is now accessible in the Investor section o the CervoMed website https://www.cervomed.com/.

In a phase 1b/2a trial subcutaneous amycretin demonstrated a safety profile similar to other incretin-based drugs . Adults ...

Danish healthcare company Novo Nordisk A/S (NVO) announced topline results from a phase 1b/2a clinical trial with amycretin, a ...